XOMA/XOMA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About XOMA

XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Ticker

XOMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Owen Hughes

Employees

13

Headquarters

Emeryville, United States

XOMA Metrics

BasicAdvanced
$300M
Market cap
-
P/E ratio
-$3.92
EPS
0.85
Beta
-
Dividend rate
$300M
0.85137
$27.00
$13.48
14K
9.452
139.09
146.552
-24.55%
-22.44%
-45.83%
-24.19%
51.653
3.647
3.645
73.10%
-49.04%
-45.50%

What the Analysts think about XOMA

Analyst Ratings

Majority rating from 3 analysts.
Buy

XOMA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-607.14% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.4M
-22.22%
Net income
-$8.5M
-57.71%
Profit margin
-607.14%
-45.63%

XOMA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.17%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.59
-$0.60
-$1.87
-$0.86
-
Expected
-$0.52
-$0.48
-$0.36
-$0.81
-$0.27
Surprise
14.34%
25.00%
416.57%
6.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for XOMA stock?

XOMA (XOMA) has a market cap of $300M as of June 15, 2024.

What is the P/E ratio for XOMA stock?

The price to earnings (P/E) ratio for XOMA (XOMA) stock is 0 as of June 15, 2024.

Does XOMA stock pay dividends?

No, XOMA (XOMA) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next XOMA dividend payment date?

XOMA (XOMA) stock does not pay dividends to its shareholders.

What is the beta indicator for XOMA?

XOMA (XOMA) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the XOMA stock price target?

The target price for XOMA (XOMA) stock is $58, which is NaN% below the current price of $. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell XOMA stock

Buy or sell XOMA stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing